Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome.
Neeck, G, Crofford, L J · Rheumatic diseases clinics of North America · 2000 · DOI
Quick Summary
This review examines how hormone systems work differently in people with ME/CFS and fibromyalgia. In ME/CFS, the stress hormone system appears to be underactive, possibly due to problems in the brain. In fibromyalgia, the opposite seems true—the stress hormone system appears overactive, likely as the body's response to chronic pain. Understanding these differences could help explain why these conditions feel so different and might guide better treatments.
Why It Matters
This study identifies fundamental biological differences between ME/CFS and fibromyalgia at the neuroendocrine level, suggesting they may require distinct therapeutic approaches rather than shared treatments. Understanding HPA axis dysfunction in ME/CFS could explain cardinal symptoms like fatigue and post-exertional malaise, and may eventually guide development of targeted interventions.
Observed Findings
Multiple laboratories worldwide have documented reduced adrenocortical responsiveness in ME/CFS patients
Deficient serotonergic activity has been suggested in ME/CFS, whereas serotonergic input normally stimulates HPA axis activity
SymPathetic nervous system hypofunction has been described in ME/CFS and may contribute to abnormal HPA axis activity
In fibromyalgia, elevated CRH neuronal activity appears to suppress growth hormone, thyroid-stimulating hormone, and gonadal function through multiple pathways
Hyperactive CRH neurons in fibromyalgia may be driven by chronic musculoskeletal pain and altered central pain processing
Inferred Conclusions
ME/CFS and fibromyalgia represent opposite patterns of HPA axis dysfunction—hypoactivity versus hyperactivity—suggesting distinct neuroendocrine disease mechanisms
In fibromyalgia, the observed hormonal pattern represents a CNS adjustment to chronic pain mediated primarily by elevated CRH activity
Deficient serotonergic and sympathetic input likely contributes to reduced HPA responsiveness in ME/CFS, though the primary locus of dysfunction remains uncertain
Remaining Questions
Is reduced adrenocortical responsiveness in ME/CFS primary (originating in CRH neurons) or secondary to dysfunction in serotonergic, noradrenergic, or sympathetic pathways?
What This Study Does Not Prove
This review does not establish causality—reduced HPA responsiveness in ME/CFS may be secondary to other pathologies rather than primary. The study does not prove that glucocorticoid replacement is ineffective; the authors note that interpreting glucocorticoid trials depends on disputed evidence of positive effects. It does not definitively identify which specific central or peripheral components of the HPA axis are primarily dysfunctional.
Tags
Symptom:PainFatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionExploratory OnlyMixed Cohort
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does glucocorticoid replacement therapy benefit ME/CFS patients, and if so, does this indicate primary adrenal insufficiency or respond paradoxically to increased negative feedback?
What triggers and sustains elevated CRH activity in fibromyalgia—is it purely pain-driven, or do altered CNS nociceptive mechanisms play an independent role?
Are the neuroendocrine patterns in each condition stable over time or do they fluctuate with disease severity and symptom burden?